---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000014"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:24:04.212204+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene posts FY2024 net loss $75.1M, cash $312.4M, NGN-401 gets EMA PRIME, trial updates

## Summary
- Cash and marketable securities $312.4M as of Dec 31, 2024; runway into H2 2027 to support NGN-401 registrational trial and pipeline.
- R&D expenses $60.9M in FY2024 (up from $44.4M) on higher Rett trial costs and headcount; net loss $75.1M vs $36.3M prior year.
- NGN-401 Phase 1/2 trial: dose fixed at 1E15 vg, age range expanded >11 years; received EMA PRIME designation.
- Anticipated milestones: regulatory update on registrational plans in H1 2025; additional interim clinical data in H2 2025.

## SEC filing metadata
- accession: 0001404644-25-000014
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/0001404644-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/ngne-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000014
- JSON: https://secwatch.observer/filing/0001404644-25-000014.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.